QuicDNA
Research type
Research Study
Full title
INTEGRATION OF LIQUID BIOPSY INTO LUNG CANCER DIAGNOSTIC PATHWAY: QuicDNA
IRAS ID
328841
Contact name
Magda Meissner
Contact email
Sponsor organisation
Aneurin Bevan University Health Board
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Cancer genomic profiling is the mainstay of personalised cancer treatment and allows clinicians to select the most appropriate treatment for the individual patient. Clinical trials have proved that targeted therapies improves patient outcomes, including survival. It is, therefore, vital for doctors and patients to receive a genomic profile with their diagnosis as early as possible, as this will direct
patients towards the most effective therapy.
In the current diagnostic pathway, following GP's referral for suspicious lung cancer, genomic analysis is requested from tissue biopsy at the lung cancer multidisciplinary(MDT) meeting around 21-28 days after the first referral. Following the MDT, genomic analysis can take 14-24 days or longer if repeat biopsies are required. The current pathway is not efficient for clinicians or patients. Patients with advanced disease often deteriorate rapidly and become too unwell or die if no treatment is received and a potential treatment opportunity is lost.
In the QuicDNA study, we propose the introduction of a non-invasive blood test for patients with high suspicion of lung cancer.
In the QuicDNA study, a blood sample (liquid biopsy) will be collected from patients with a high suspicion of lung cancer after their GP's referral and before collection of biopsy and will be analysed in the All Wales Medical Genomics Service (AWMGS) laboratory, based at the Cardiff & Vale University Health Board in Cardiff for the detection of circulating tumour DNA (ctDNA).
This study aims to evaluate whether ctDNA testing performed at an early stage in the lung cancer diagnostic pathway can shorten time to treatment compared to the SoC diagnostic pathway and expedite the planning of target treatment.REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
23/EM/0159
Date of REC Opinion
28 Jul 2023
REC opinion
Further Information Favourable Opinion